Table 3.
Clinical outcomes during hospitalization.
| 2020 |
2021 |
|||||||
|---|---|---|---|---|---|---|---|---|
| Variables | Total (n = 425) | HIV infected (n = 86) | non-HIV infected (n = 339) | p-value | Total (n = 219) | HIV infected (n = 44) | non-HIV infected (n = 175) | p-value |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |||
| Outcomes | ||||||||
| Septic shock | 81 (19.1%) | 18 (20.9%) | 63 (18.6%) | 0.733 | 31 (14.2%) | 6 (13.6%) | 25 (14.3%) | >0.999 |
| Adult respiratory distress syndrome | 88 (20.7%) | 16 (18.6%) | 72 (21.2%) | 0.697 | 71 (32.4%) | 15 (34.1%) | 56 (32.0%) | 0.932 |
| Acute myocardial infarction | 6 (1.4%) | 2 (2.3%) | 4 (1.2%) | 0.350 | 2 (0.9%) | 0 (0.0%) | 2 (1.1%) | >0.999 |
| Nosocomial infection | 73 (17.2%) | 14 (16.3%) | 59 (17.4%) | 0.931 | 41 (18.7%) | 9 (20.5%) | 32 (18.3%) | 0.910 |
| Deep vein thrombosis | 12 (2.8%) | 2 (2.3%) | 10 (2.9%) | >0.999 | 6 (2.7%) | 1 (2.3%) | 5 (2.9%) | >0.999 |
| Pulmonary thromboembolism | 24 (5.6%) | 4 (4.7%) | 20 (5.9%) | 0.798 | 15 (6.8%) | 6 (13.6%) | 9 (5.1%) | 0.086 |
| Renal replacement therapy requirement | 53 (12.5%) | 13 (15.1%) | 40 (11.8%) | 0.516 | 26 (11.9%) | 6 (13.6%) | 20 (11.4%) | 0.885 |
| Admission to the ICU | 178 (42.0%) | 37 (43.5%) | 141 (41.6%) | 0.841 | 94 (43.1%) | 17 (38.6%) | 77 (44.3%) | 0.616 |
| Length of stay (days)a | 9.0 (4.0, 21.0) | 9.0 (4.0, 18.0) | 9.0 (4.0, 23.0) | 0.512 | 10.5 (5.0, 16.8) | 11.0 (5.0, 18.0) | 10.0 (5.0, 16.0) | 0.906 |
| Mechanical ventilation support | 136 (32.5%) | 30 (35.7%) | 106 (31.7%) | 0.572 | 71 (32.4%) | 15 (34.1%) | 56 (32.0%) | 0.932 |
| Death | 84 (19.8%) | 24 (27.9%) | 60 (17.7%) | 0.049 | 55 (25.1%) | 11 (25.0%) | 44 (25.1%) | >0.999 |
a
Median (Interquartile Range ‒ IQR). Statistical tests: Wilcoxon rank-sum test; Chi-Square test of independence; Fisher's exact test.